Replimune Group, Inc.
corporate_fare Company Profile
Replimune Group, Inc. (NASDAQ:REPL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for REPL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 14 rated 8 or above. Recent SEC coverage for REPL spans 10-Q, 8-K, SCHEDULE 13D/A, 4.
Recent high-impact activity:
- Replimune 10-Q: $307.8M Cash, Quarterly Loss Narrows to $57.1M, $15M Hercules Draw
- Replimune Posts Q2 FY2027 Results: First TUDRIQEV Launch Metrics, $307.8M Cash
- Replimune Posts $57.1M Quarterly Loss as TUDRIQEV Launch Reaches 15+ Institutions
- Replimune 10-Q: Going Concern Lifted After $141M Raise and FDA Approval
- Replimune Posts Q1 Loss, Appoints Chief Commercial Officer Ahead of TUDRIQEV Launch
Financial Snapshot
Short Interest & Short Volume
8.31 days to coverFINRA reported short interest of 24,609,876 shares in REPL as of the October 30, 2026 settlement, a 6.2% increase from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 49.2% of REPL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for REPL, detected from its recent SEC filings · based on capital-structure filings through 2026-08-10.
$150M Offering Priced at Premium · Net Proceeds of ~$140.5M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →